As of Friday close, Adicet Bio Inc.’s (NASDAQ:ACET) stock was down -$0.28, moving down -3.63 percent to $7.43. The average number of shares traded per day over the past five days has been 1,280,200 shares. 2 times new highs have been achieved over the past 5 days, with a $0.29 gain in that time frame. In the last twenty days, the average volume was 664,120, while in the previous 50 days, it was 558,664.
Since last month, ACET stock retreated -8.72%. Shares of the company fell to $6.82 on 03/10/23, the lowest level in the past month. A 52-week high of $21.87 was reached on 02/02/23 after having rallying from a 52-week low of $6.82. Since the beginning of this year, ACET’s stock price has dropped by -16.89% or -$1.51, and marked a new high 3 times. However, the stock has declined by -66.03% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
ACET stock investors should be aware that Adicet Bio Inc. (ACET) stock had its last reported insider trading activity 31 days ago on Feb 15. Healey Don, the Chief Technology Officer of the company, disposed of 4,533 shares for $7.57 on Feb 15. It resulted in a $34,327 divestment by the insider. Healey Don sold 10,467 shares at an average price of $7.98 on Feb 10. The insider now owns 71,101 shares following the transaction. On Nov 10, President & CEO Schor Chen sold 30,000 shares at $20.06 apiece. The transaction was valued at $601,920.
Valuation Metrics
The stock’s beta is 2.27. Besides these, the trailing price-to-sales (P/S) ratio of 10.88, the price-to-book (PB) ratio of 0.97.
The latest dividend of $0.01 per share was paid out, remained unchanged from last year’s $0.01.
Financial Health
In the three months ended December 30, Adicet Bio Inc.’s quick ratio stood at 16.60, while its current ratio was 16.60, showing that the company is able to pay off its debt. Based on annual data, ACET earned $97.54 million in gross profit and brought in $24.99 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -20.20%. Return on equity (ROE) for the past 12 months was -18.20%.
While analysts expected Adicet Bio Inc. to report -$0.28 quarterly earnings, the actual figure was -$0.72 per share, beating the consensus estimate by -157.10%. During the quarter, the company generated -$30.43 million in EBITDA. The liabilities of Adicet Bio Inc. were 38.35 million at the end of its most recent quarter ended December 30, and its total debt was $21.02 million. The value of shareholders’ equity is $42.95 million.
Technical Picture
This quick technical analysis looks at Adicet Bio Inc.’s (ACET) price momentum. With a historical volatility rate of 57.85%, the RSI 9-day stood at 41.75% on 17 March.
With respect to its five-day moving average, the current Adicet Bio Inc. price is up by +4.06% percent or $0.29. At present, ACET shares trade -5.83% below its 20-day simple moving average and -57.13% percent below its 100-day simple moving average. However, the stock is currently trading approximately -12.59% below its SMA50 and -37.14% below its SMA200.
Stochastic coefficient K was 59.68% and Stochastic coefficient D was 66.90%, while ATR was 0.52. Given the Stochastic reading of 45.69% for the 14-day period, the RSI (14) reading has been calculated as 42.08%. As of today, the MACD Oscillator reading stands at 0.01, while the 14-day reading stands at -0.02.
Analyst Ratings
JP Morgan launched its rating on Adicet Bio Inc. (NASDAQ: ACET) to an Overweight in a note to investors on September 21, 2022. Adicet Bio Inc. (ACET) has been rated Buy by analysts. According to 0 brokerage firms, ACET is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Adicet Bio Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $27.00, the current consensus forecast for the stock is $19.00 – $38.00. Based on these forecasts, analysts predict Adicet Bio Inc. (ACET) will achieve an average price target of $26.91.